breast cancer tnbc cell line mda mb 231  (ATCC)

Journal: RSC Advances

Article Title: Mononuclear Mg( ii ) and Ca( ii ) metallocarboxylates of N -phthaloyl- γ -aminobutyric acid: synthesis, characterization, ds-DNA binding, preliminary anticancer evaluation against MDA-MB-231 cells, and computational studies

doi: 10.1039/d6ra07684j

Figure Lengend Snippet: Anticancer activity of NY0, NY1 and NY2 against triple-negative MDA-MB-231 breast cancer cell lines: (a) cytotoxic effect against MDA-MB-231 cell lines and (b) viability against normal skin HaCaT cells.

Article Snippet: The triple-negative breast cancer (TNBC) cell line MDA-MB-231 (ATCC HTB-26) and the normal human breast epithelial cell line MCF-10A (ATCC CRL-10317) used in this study were purchased from the American Type Culture Collection (ATCC), USA.

Techniques: Activity Assay

Journal: RSC Advances

Article Title: Mononuclear Mg( ii ) and Ca( ii ) metallocarboxylates of N -phthaloyl- γ -aminobutyric acid: synthesis, characterization, ds-DNA binding, preliminary anticancer evaluation against MDA-MB-231 cells, and computational studies

doi: 10.1039/d6ra07684j

Figure Lengend Snippet: IC 50 values for the treated MDA-MB-231 cancer and MCF-10A normal cells

Article Snippet: The triple-negative breast cancer (TNBC) cell line MDA-MB-231 (ATCC HTB-26) and the normal human breast epithelial cell line MCF-10A (ATCC CRL-10317) used in this study were purchased from the American Type Culture Collection (ATCC), USA.

Techniques:

Journal: Frontiers in Public Health

Article Title: Evaluation of the radiomodifying effects of Ginkgo biloba in radioresistant triple negative breast cancer cells

doi: 10.3389/fpubh.2026.1952136

Figure Lengend Snippet: Concentration- and time dependent effects of Ginkgo biloba (GB) treatment, alone and in combination with 3 Gy irradiation, on the viability of MDA-MB-231 cells as determined by MTT assay. Cell viability was assessed at 24 h (A) , 48 h (B) and 72 h (C) following treatment with increasing concentrations of GB. Data are presented as mean ± SD from three independent biological experiments. Asterisks indicate significant differences compared with the corresponding untreated control (0 μg/mL GB): p < 0.05 (*) and p < 0.01 (**).

Article Snippet: The human triple-negative breast cancer (TNBC) parental cell line MDA-MB-231 (HTB-26, ATCC, Manassas, VA, USA) was cultured in DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin–streptomycin.

Techniques: Concentration Assay, Irradiation, MTT Assay, Control

Journal: Frontiers in Public Health

Article Title: Evaluation of the radiomodifying effects of Ginkgo biloba in radioresistant triple negative breast cancer cells

doi: 10.3389/fpubh.2026.1952136

Figure Lengend Snippet: Effects of Ginkgo biloba (GB) treatment, alone and in combination with 3 Gy irradiation, on intracellular reactive oxygen species (ROS) generation in MDA-MB-231 cells, assessed by flow cytometry using CellROX ® Green staining. Cells treated with TBHP (positive control) and untreated cells (negative control) are shown in panel (A) . Cells were treated with increasing concentrations of GB (0–300 μg/mL), and the percentage of live cells (B) and intracellular ROS levels (C) were evaluated in non-irradiated and irradiated groups. Data are presented as mean ± SD from three independent biological experiments.

Article Snippet: The human triple-negative breast cancer (TNBC) parental cell line MDA-MB-231 (HTB-26, ATCC, Manassas, VA, USA) was cultured in DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin–streptomycin.

Techniques: Irradiation, Flow Cytometry, Staining, Positive Control, Negative Control

Journal: Frontiers in Public Health

Article Title: Evaluation of the radiomodifying effects of Ginkgo biloba in radioresistant triple negative breast cancer cells

doi: 10.3389/fpubh.2026.1952136

Figure Lengend Snippet: Effects of Ginkgo biloba (GB) treatment on the percentage of live MDA-MB-231 cells assessed by apoptosis assay using flow cytometry following exposure to 3 Gy irradiation. Cells were treated with increasing concentrations of GB (0–300 μg/mL), and viable cell populations were analyzed at 24 h (A) , 48 h (B) , and 72 h (C) hours in both non-irradiated and irradiated groups. Data are presented as mean ± SD from three independent biological experiments.

Article Snippet: The human triple-negative breast cancer (TNBC) parental cell line MDA-MB-231 (HTB-26, ATCC, Manassas, VA, USA) was cultured in DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin–streptomycin.

Techniques: Apoptosis Assay, Flow Cytometry, Irradiation

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP exerts cytotoxicity in TNBC cells. (A) Chemical structure of CEP. (B) CEP inhibited TNBC cell viability. The effect of CEP treatment on TNBC cell viability after 24, 48 and 72 h. (C) CEP inhibited clonogenicity of MDA-MB-231 and Hs578T cells. n=3; *P < 0.05, **P < 0.01 and ***P < 0.001 vs. control. CEP, cepharanthine; TNBC, triple-negative breast cancer.

Article Snippet: The TNBC cell lines MDA-MB-231 (cat. no. CL-0150; Procell Life Science & Technology Co., Ltd.) and Hs578T (cat. no. CL-0114; Procell Life Science & Technology Co., Ltd.) were cultured in high-glucose DMEM medium (cat. no. C11965500BT; Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (cat. no. 164210; Procell Life Science & Technology Co., Ltd.) and 1% penicillin/streptomycin (cat. no. 15140122; Gibco; Thermo Fisher Scientific, Inc.).

Techniques: Control

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP induces apoptosis in triple-negative breast cancer cells. Flow cytometric quantification of apoptosis induced by CEP in (A) MDA-MB-231 and (B) Hs578T cells (n=3; 48 h). **P<0.01 and ***P < 0.001 vs. control. CEP, cepharanthine; ns, not significant.

Article Snippet: The TNBC cell lines MDA-MB-231 (cat. no. CL-0150; Procell Life Science & Technology Co., Ltd.) and Hs578T (cat. no. CL-0114; Procell Life Science & Technology Co., Ltd.) were cultured in high-glucose DMEM medium (cat. no. C11965500BT; Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (cat. no. 164210; Procell Life Science & Technology Co., Ltd.) and 1% penicillin/streptomycin (cat. no. 15140122; Gibco; Thermo Fisher Scientific, Inc.).

Techniques: Control

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP induces ΔΨm loss in triple-negative breast cancer cells. (A) MDA-MB-231 (10 µM; n=3; 24 h) and (B) Hs578T cells (4 µM; n=3; 24 h). Scale bar, 100 µM. CEP, cepharanthine.

Article Snippet: The TNBC cell lines MDA-MB-231 (cat. no. CL-0150; Procell Life Science & Technology Co., Ltd.) and Hs578T (cat. no. CL-0114; Procell Life Science & Technology Co., Ltd.) were cultured in high-glucose DMEM medium (cat. no. C11965500BT; Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (cat. no. 164210; Procell Life Science & Technology Co., Ltd.) and 1% penicillin/streptomycin (cat. no. 15140122; Gibco; Thermo Fisher Scientific, Inc.).

Techniques:

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP upregulates NOXA and downregulates Bcl-2 expression in triple-negative breast cancer cells. CEP upregulated NOXA and downregulated Bcl-2 expression in (A) MDA-MB-231 cells (n=3; 24 h) and (B) Hs578T cells (n=3; 24 h). *P<0.05, **P<0.01 and ***P<0.001 vs. control. CEP, cepharanthine; NOXA, phorbol-12-myristate-13-acetate-induced protein 1; ns, not significant.

Article Snippet: The TNBC cell lines MDA-MB-231 (cat. no. CL-0150; Procell Life Science & Technology Co., Ltd.) and Hs578T (cat. no. CL-0114; Procell Life Science & Technology Co., Ltd.) were cultured in high-glucose DMEM medium (cat. no. C11965500BT; Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (cat. no. 164210; Procell Life Science & Technology Co., Ltd.) and 1% penicillin/streptomycin (cat. no. 15140122; Gibco; Thermo Fisher Scientific, Inc.).

Techniques: Expressing, Control

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: Proteomic profiling of MDA-MB-231 cells following CEP treatment. (A) The 20 most significantly downregulated Gene Ontology cellular components with CEP treatment. (B) Significantly downregulated Kyoto Encyclopedia of Genes and Genomes pathways with CEP treatment. CEP, cepharanthine.

Article Snippet: The TNBC cell lines MDA-MB-231 (cat. no. CL-0150; Procell Life Science & Technology Co., Ltd.) and Hs578T (cat. no. CL-0114; Procell Life Science & Technology Co., Ltd.) were cultured in high-glucose DMEM medium (cat. no. C11965500BT; Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (cat. no. 164210; Procell Life Science & Technology Co., Ltd.) and 1% penicillin/streptomycin (cat. no. 15140122; Gibco; Thermo Fisher Scientific, Inc.).

Techniques:

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP treatment activates TFEB in triple-negative breast cancer cells. (A) CEP triggers TFEB nuclear translocation in MDA-MB-231 cells (10 µM; 24 h). (B) CEP triggers TFEB nuclear translocation in Hs578T cells (4 µM; 24 h). Scale bar, 25 µm; n=5. **P<0.01 vs. control. TFEB, transcription factor EB; CEP, cepharanthine.

Article Snippet: The TNBC cell lines MDA-MB-231 (cat. no. CL-0150; Procell Life Science & Technology Co., Ltd.) and Hs578T (cat. no. CL-0114; Procell Life Science & Technology Co., Ltd.) were cultured in high-glucose DMEM medium (cat. no. C11965500BT; Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (cat. no. 164210; Procell Life Science & Technology Co., Ltd.) and 1% penicillin/streptomycin (cat. no. 15140122; Gibco; Thermo Fisher Scientific, Inc.).

Techniques: Translocation Assay, Control

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP does not induce LMP, increase lysosomal pH or destabilize lysosomal membrane-bound enzymes in triple-negative breast cancer cells. (A) CEP does not induce LMP, as evidenced by a dispersion of dextran, in MDA-MB-231 (10 µM; 24 h) and Hs578T cells (4 µM; 24 h). Scale bar, 25 µm. (B) CEP does not elevate lysosomal pH in the MDA-MB-231 (10 µM; 24 h) and Hs578T cell lines (4 µM; 24 h). Scale bar, 25 µm. (C) CEP does not induce lysosomal membrane-bound enzymes degradation in the MDA-MB-231 (10 µM; n=3; 24 h) and Hs578T cell lines (4 µM; n=3; 24 h). CEP, cepharanthine; ASAH1, acid ceramidase; SMPD1, sphingomyelin phosphodiesterase; ns, not significant.

Article Snippet: The TNBC cell lines MDA-MB-231 (cat. no. CL-0150; Procell Life Science & Technology Co., Ltd.) and Hs578T (cat. no. CL-0114; Procell Life Science & Technology Co., Ltd.) were cultured in high-glucose DMEM medium (cat. no. C11965500BT; Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (cat. no. 164210; Procell Life Science & Technology Co., Ltd.) and 1% penicillin/streptomycin (cat. no. 15140122; Gibco; Thermo Fisher Scientific, Inc.).

Techniques: Membrane, Dispersion

Journal: Molecular Medicine Reports

Article Title: Cepharanthine inhibits lysosomes and induces apoptosis in triple-negative breast cancer cells

doi: 10.3892/mmr.2026.13899

Figure Lengend Snippet: CEP binds to and inhibits lysosomal enzymes. (A) Structurally altered peptides in the MDA-MB-231 cell line upon CEP treatment (10 µM, 1 h; FC >1.5 or <0.667, false discovery rate <1, P<0.01; n=3). (B) CEP treatment suppresses the maturation of CTSB and CTSD (24 h). *P<0.05, **P<0.01 and ***P<0.001 vs. control. CEP, cepharanthine; FC, fold change; CTSD, cathepsin D; CTSB, cathepsin B; pro-CTSB pro-cathepsin B; pro-CTSD, pro-cathepsin D; i-CTSB, inactive cathepsin B; m-CTSB, mature cathepsin B; m-CTSD, mature cathepsin D.

Article Snippet: The TNBC cell lines MDA-MB-231 (cat. no. CL-0150; Procell Life Science & Technology Co., Ltd.) and Hs578T (cat. no. CL-0114; Procell Life Science & Technology Co., Ltd.) were cultured in high-glucose DMEM medium (cat. no. C11965500BT; Gibco; Thermo Fisher Scientific, Inc.), supplemented with 10% fetal bovine serum (cat. no. 164210; Procell Life Science & Technology Co., Ltd.) and 1% penicillin/streptomycin (cat. no. 15140122; Gibco; Thermo Fisher Scientific, Inc.).

Techniques: Control